Litigation Details for Allergan USA, Inc. v. MSN Laboratories Private Limited (D. Del. 2019)
✉ Email this page to a colleague
Allergan USA, Inc. v. MSN Laboratories Private Limited (D. Del. 2019)
| Docket | ⤷ Try a Trial | Date Filed | 2019-09-13 |
| Court | District Court, D. Delaware | Date Terminated | 2023-10-12 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Parties | MSN PHARMACEUTICALS, INC. | ||
| Patents | 10,188,632; 6,251,910; 6,346,532; 6,525,060; 7,250,419; 7,265,124; 7,741,356; 7,786,158; 8,344,011; 8,425,934; 8,691,860; 9,115,091; 9,364,489; 9,675,587; 9,789,125 | ||
| Attorneys | Jack B. Blumenfeld | ||
| Firms | Morris, Nichols, Arsht & Tunnell | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Allergan USA, Inc. v. MSN Laboratories Private Limited
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for Allergan USA, Inc. v. MSN Laboratories Private Limited (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-09-13 | 1 | Complaint | '587 patent"), 9,789,125 ("the '125 patent"), and/or 10,188,632 ("the…860 patent, the '091 patent, the '489 patent, the '587 patent, the '125 patent, and…860 patent, the '091 patent, the '489 patent, the '587 patent, the '125 patent, and…860 patent, the '091 patent, the '489 patent, the '587 patent, the '125 patent, and…860 patent, the '091 patent, the '489 patent, the '587 patent, the '125 patent, and | External link to document |
| 2021-01-11 | 140 | Opinion - Memorandum Opinion | the ʼ489 patent”), 9,789,125 (“the ʼ125 patent”), 9,675,587 (“the ʼ587 patent”), and 10,188,632 (“the ʼ632…terms in U.S. Patent Nos. 8,691,860, 9,115,091, 9,364,489, 9,789,125, 9,675,587, and 10,188,632.. Signed by…Crystalline Form Patents are the ʼ860 patent, the ʼ091 patent, the ʼ489 patent, and the ʼ125 patent. The Abuse-Deterrent… terms in U.S. Patent Nos. 8,691,860 (“the ’860 patent”), 9,115,091 (“the ʼ091 patent”), 9,364,489 (“…Abuse-Deterrent Patents are the ʼ587 patent and the ʼ632 patent. The parties agreed on the constructions | External link to document |
| 2021-02-08 | 147 | Notice of Service | Initial Invalidity Contentions for U.S. Patent No. 9,675,587 filed by Zydus Pharmaceuticals (USA) Inc…2019 12 October 2023 1:19-cv-01727 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2022-06-02 | 352 | Stipulation-General (See Motion List for Stipulation to Extend Time) | STIPULATION Regarding U.S. Patent Nos. 8,691,860, 9,115,091, 9,364,489, 9,789,125 and 7,741,356 by Allergan Holdings…2019 12 October 2023 1:19-cv-01727 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2022-06-17 | 357 | Notice of Service | Invalidity and Unenforceability of U.S. Patent Nos. 9,675,587, 10,188,632, 11,007,179, 11,090,291, 111,160,792…2019 12 October 2023 1:19-cv-01727 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2022-07-18 | 369 | Notice of Service | Regarding Noninfringement of U.S. Patent Nos. 9,675,587 and 10,188,632 (with Exhibits 1-2) [CONFIDENTIAL…2019 12 October 2023 1:19-cv-01727 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
